$700,000 grant to advance use of stem cells to study rare disease

May 20, 2015

Dr. Bill Stanford has been awarded more than US$700,000 over three years from the United States Congressionally Directed Medical Research Program to use stem cells to study the rare genetic disease Tuberous sclerosis and the related lung tumor Lymphangioleiomyomatosis (LAM). Tuberous sclerosis is characterized by the formation of benign skin tumours and other organs, however LAM tumours are life-threatening due to their destruction of the lungs. By genetically reprogramming skin cells from patients with Tuberous sclerosis and engineering two different TSC2 mutations in additional male and female stem cell lines, Dr. Stanford’s lab has been able to generate stem cells that can model the development of the disease in the laboratory and help with the development of new drugs.
Co-investigators: Arnold Kristof

Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with its faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. Support our research. Give to the Tender Loving Research campaign.

For further information, please contact

Lois Ross
Senior Communications Specialist
Ottawa Hospital Research Institute
Office: 613-737-8899 x73687
Cell: 613-297-8315